RESULTS OF PROSPECTIVE INVESTIGATION OF THE PROGNOSTIC VALUE OF HYPERSYMPATHICOTONIA FOR NORMATENSIVE PATIENTS WITH CHRONIC MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS
https://doi.org/10.24884/1561-6274-2007-11-2-59-63
Abstract
THE AIM of the work was to assess the prognostic significance of sympathetic hyperactivity in normotensive patients with mesangial proliferative glomerulonephritis (MP CGN). PATIENTS AND METHODS. The investigation included 23 patients with MP CGN. Puncture biopsy of the kidney was fulfilled in all the patients at inclusion in the investigation. At this stage and laterannually during 5 years the following parameters were studied: clinical analysis of blood and urine, daily proteinuria, GFR was calculated by the Cockroft-Gault formula, Holter monitoring of ECG was fulfilled with an analysis of the heart rate variability. The end points were considered to be: emergence of AH, appearance of CGN symptoms, development of acute cardiovascular and cerebrovascular events. RESULTS. In patients with hyperactivity of the sympathetic nervous system arterial hypertension was developing on average not only one year earlier, but also the frequency of its formation in the fourth year of observations was 3 times as high (27.3% against 8.3%) as the same index in the group of comparison. By the end of the fifth year of observations the summary frequency of hypertension in patients with sympathetic hyperactivity was 72.7%, while in the group of comparison it was as low as 46.7%. In patients with sympathetic hyperactivity the decreased function of the kidneys (18.2% against 8.3%) was observed earlier than in the group of comparison. The summary frequency of chronic renal failure in patients with hypersympathicotonia was 36.4% by the end of the fifth year of observation, while in the group of comparison it was only 8.3%. The incidence of lethal myocardial infarction in patients with sympathetic hyperactivity proved to be higher that without it (9.1% against 0%). CONCLUSION. The presence of HSHS in normatensive patients with MP CGN potentially facilitates the development of cardiovascular disorders and more rapid progression of the development of renal dysfunction.
References
1. Mashio G, Marcantoni C. Hypertension and progression of renal disease. J Nephrol 2000; 13: 905-918
2. Смирнов АВ, Добронравов ВА, Бодур-Ооржак АШ и др. Эпидемиология и факторы риска хронических болезней почек: региональный уровень общей проблемы. Тер арх 2005; 6: 27-32
3. Іванов Д. Хронічне захворювання нирок. Діагностика та лікувальна тактика за даними доказової медицини. Ліки України 2005; 5: 19-21
4. Epstein M, Tobe S. What is the optimal strategy to intensify blood pressure control and prevent progression of renal disease? Current Hypertension Reports 2001; 3: 422-428
5. National Kidney Foundation. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Executive Summary. New York; 2002: 94 p
6. Кузьмин ОБ, Пугаева МО, Чуб СВ, Ландарь ЛН. Почечные механизмы эссенциальной гипертонии. Нефрология 2005; 9 (2): 23-29
7. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int 2000; 57 [Suppl 75]: S2-S6
8. Іванов ДД. Пригнічення гіперактивності симпатичної системи - шлях до гальмування прогресування хронічного захворювання нирок. Ліки України 2005; 9: 87-89
9. Иванов ДД. Лечение гипертензии и органопротекция. Ренальная органопротекция. Мистецтво лікування 2005; 9: 48-55
10. Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 2002; 4 (3): 256-260
11. Erami C, Zhang H, Tanoue A et al. Adrenergic catecholamine trophic activity contributes to flow-mediated arterial remodeling. Am J Physiol 2005; 289 (2): H744-H753
12. Zoccali C, Mallamaci F, Parlengo S et al. Plasma norepinephrine predict survival and incident cardiovascular events in patients with end stage renal disease. Circulation 2002; 105(11): 1354-1359
13. Ridao N, Luno J, Garcia de Vinuesa S et al. Prevalence of hypertension in renal disease. Neprol Dial Transplant 2001; [Suppl 1]: 12-17
14. Campese VM, Shaohua Ye, Huinqin Zhongetal. Reactive oxygen species stimulate central and peripheral sympathetic nervous system. Am J Physiol 2004; 287(2): H695-H703
15. Eppel GA, Malpas SC, Denton KM, Evans RG. Neural control of renal medullary perfusion. Clin Exp Pharmacol Physiol 2004; 31 (5-6): 387-396
16. Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure. J Clin Invest 1997; 99 (3): 540-548
17. Eikelis N, Schlaich M, Aggarwal A et al. Interaction between leptin and human sympathetic nervous system. Hypertension 2003; 41 (5): 1072-1079
18. Hansberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end stage renal disease. Circulation 2002; 106 (15): 1974-1979
19. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14(12): 3239-3244
20. Modlinger PC, Wilcox CS, Aslam S. Nitric oxide, oxidative stress and progressive of chronic renal failure. Semin Nephrol 2004; 24 (4): 354-365
21. Tinucci T, Abrahao SB, Santello JL, Mion D. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15 (6): 401-406
22. Ruggenenti P, Perna A, Loziga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN 2): multicentre, randomized controlled trial. Lancet 2005; 365 (9463): 939-946
23. Rump LC. The role of sympathetic nervous activity in chronic renal failure. J Сlin Вasic Сardiol 2001; 4: 179-181
Review
For citations:
Mukhin I.V. RESULTS OF PROSPECTIVE INVESTIGATION OF THE PROGNOSTIC VALUE OF HYPERSYMPATHICOTONIA FOR NORMATENSIVE PATIENTS WITH CHRONIC MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS. Nephrology (Saint-Petersburg). 2007;11(2):59-63. (In Russ.) https://doi.org/10.24884/1561-6274-2007-11-2-59-63
Views:
352
Email this article 